Blocking Ang2 action with neutralizing antibodies has been shown to suppress Ang2-mediated vascular effects and improve outcomes in preclinical models of a range of diseases, including sepsis, acute and chronic myocardial damage following infarction and inflammatory lung disease (19, 20, 21). Here, ANGPT2 is linked to infarction.